{"id":"https://openalex.org/W2909497384","doi":"https://doi.org/10.1007/s40264-018-00788-w","title":"Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma","display_name":"Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma","alternate_titles":[],"publication_year":2019,"publication_date":"2019-01-16","ids":{"openalex":"https://openalex.org/W2909497384","doi":"https://doi.org/10.1007/s40264-018-00788-w","mag":"2909497384","pmid":"https://pubmed.ncbi.nlm.nih.gov/30649752","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6520328"},"language":"en","primary_location":{"id":"doi:10.1007/s40264-018-00788-w","doi":"https://doi.org/10.1007/s40264-018-00788-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40264-018-00788-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40264-018-00788-w.pdf","source":{"id":"https://openalex.org/S49488433","display_name":"Drug Safety","issn_l":"0114-5916","issn":["0114-5916","1179-1942"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Safety","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2909497384"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40264-018-00788-w.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101792594","display_name":"Mats Carlsson","orcid":"https://orcid.org/0000-0002-1232-4681","observed_orcids":["https://orcid.org/0000-0002-1232-4681"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Mats Carlsson","raw_affiliation_strings":["Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, M\u00f6lndal, 431 83, Sweden. Mats.Carlsson@astrazeneca.com","Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, M\u00f6lndal, 431 83, Sweden"],"raw_orcid":"https://orcid.org/0000-0002-1232-4681","affiliations":[{"raw_affiliation_string":"Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, M\u00f6lndal, 431 83, Sweden. Mats.Carlsson@astrazeneca.com","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, M\u00f6lndal, 431 83, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040253604","display_name":"Martin Braddock","orcid":"https://orcid.org/0000-0001-8152-3580","observed_orcids":["https://orcid.org/0000-0001-8152-3580"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin Braddock","raw_affiliation_strings":["Global Medicines Development, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yuling Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yuling Li","raw_affiliation_strings":["Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100669500","display_name":"Jihong Wang","orcid":"https://orcid.org/0000-0001-9271-0218","observed_orcids":["https://orcid.org/0000-0001-9271-0218"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jihong Wang","raw_affiliation_strings":["Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066497879","display_name":"Weichen Xu","orcid":"https://orcid.org/0000-0002-2198-1122","observed_orcids":["https://orcid.org/0000-0002-2198-1122"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Weichen Xu","raw_affiliation_strings":["Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, MD, 20878, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nicholas White","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicholas White","raw_affiliation_strings":["Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Granta Park, Great Abington, Cambridge, CB21 6GH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Granta Park, Great Abington, Cambridge, CB21 6GH, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088540608","display_name":"Ayman Megally","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayman Megally","raw_affiliation_strings":["Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021970950","display_name":"Gillian Hunter","orcid":"https://orcid.org/0000-0002-1953-0058","observed_orcids":["https://orcid.org/0000-0002-1953-0058"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gillian Hunter","raw_affiliation_strings":["Biometrics and Information Sciences, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biometrics and Information Sciences, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068913631","display_name":"Gene Colice","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gene Colice","raw_affiliation_strings":["Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5101792594"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":3760,"currency":"USD","value_usd":3760},"apc_paid":{"value":3760,"currency":"USD","value_usd":3760},"fwci":2.0639,"has_fulltext":true,"cited_by_count":22,"citation_normalized_percentile":{"value":0.86147293,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"42","issue":"6","first_page":"769","last_page":"784"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.5210000276565552,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.5210000276565552,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.23600000143051147,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.08950000256299973,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tralokinumab","display_name":"tralokinumab","score":1.0},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7879999876022339},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8550000190734863},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.8610000014305115},{"id":"https://openalex.org/keywords/anaphylaxis","display_name":"anaphylaxis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/il-13","display_name":"IL-13","score":0.8199999928474426},{"id":"https://openalex.org/keywords/severe-uncontrolled-asthma","display_name":"severe uncontrolled asthma","score":0.8679999709129333},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8270000219345093},{"id":"https://openalex.org/keywords/fab-arm-exchange","display_name":"Fab-arm exchange","score":0.8640000224113464},{"id":"https://openalex.org/keywords/oligosaccharide-structure","display_name":"oligosaccharide structure","score":0.9419999718666077},{"id":"https://openalex.org/keywords/hybrid-antibodies","display_name":"hybrid antibodies","score":0.6460000276565552},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.43799999356269836}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8453116416931152},{"id":"https://openalex.org/C2775933838","wikidata":"https://www.wikidata.org/wiki/Q168800","display_name":"Anaphylaxis","level":3,"score":0.6574441194534302},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5922811031341553},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5416065454483032},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.452706515789032},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.45044389367103577},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.44515591859817505},{"id":"https://openalex.org/C199475168","wikidata":"https://www.wikidata.org/wiki/Q1539689","display_name":"MedDRA","level":4,"score":0.42768731713294983},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41340571641921997},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3840019702911377},{"id":"https://openalex.org/C207480886","wikidata":"https://www.wikidata.org/wiki/Q42982","display_name":"Allergy","level":2,"score":0.28531962633132935},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09940236806869507},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.06495097279548645},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000519","descriptor_name":"alpha-Galactosidase","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000707","descriptor_name":"Anaphylaxis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D000707","descriptor_name":"Anaphylaxis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000917","descriptor_name":"Antibody Formation","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D001249","descriptor_name":"Asthma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001249","descriptor_name":"Asthma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1007/s40264-018-00788-w","doi":"https://doi.org/10.1007/s40264-018-00788-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40264-018-00788-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40264-018-00788-w.pdf","source":{"id":"https://openalex.org/S49488433","display_name":"Drug Safety","issn_l":"0114-5916","issn":["0114-5916","1179-1942"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Safety","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5528230","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6520328","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:30649752","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30649752","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug safety","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:pubmedcentral.nih.gov:6520328","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6520328/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Saf","raw_type":"Text"},{"id":"pmh:oai:RePEc:spr:drugsa:v:42:y:2019:i:6:d:10.1007_s40264-018-00788-w","doi":null,"is_oa":false,"landing_page_url":"http://link.springer.com/10.1007/s40264-018-00788-w","pdf_url":null,"source":{"id":"https://openalex.org/S4306401271","display_name":"RePEc: Research Papers in Economics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I77793887","host_organization_name":"Federal Reserve Bank of St. Louis","host_organization_lineage":["https://openalex.org/I77793887"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s40264-018-00788-w","doi":"https://doi.org/10.1007/s40264-018-00788-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40264-018-00788-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40264-018-00788-w.pdf","source":{"id":"https://openalex.org/S49488433","display_name":"Drug Safety","issn_l":"0114-5916","issn":["0114-5916","1179-1942"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Safety","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2909497384.pdf","grobid_xml":"https://content.openalex.org/works/W2909497384.grobid-xml"},"referenced_works_count":50,"referenced_works":["https://openalex.org/W1520693665","https://openalex.org/W1547997448","https://openalex.org/W1555361166","https://openalex.org/W1600514810","https://openalex.org/W1630159102","https://openalex.org/W1979006187","https://openalex.org/W1986864699","https://openalex.org/W2000768707","https://openalex.org/W2008138329","https://openalex.org/W2017515622","https://openalex.org/W2018795884","https://openalex.org/W2023654523","https://openalex.org/W2036075099","https://openalex.org/W2037840717","https://openalex.org/W2038319340","https://openalex.org/W2044410500","https://openalex.org/W2047130177","https://openalex.org/W2048947268","https://openalex.org/W2050656150","https://openalex.org/W2052951012","https://openalex.org/W2057388389","https://openalex.org/W2057390178","https://openalex.org/W2065801967","https://openalex.org/W2075166329","https://openalex.org/W2082194217","https://openalex.org/W2087894213","https://openalex.org/W2094955456","https://openalex.org/W2106183724","https://openalex.org/W2115525058","https://openalex.org/W2124847934","https://openalex.org/W2128393222","https://openalex.org/W2140035322","https://openalex.org/W2140341488","https://openalex.org/W2141632745","https://openalex.org/W2142564546","https://openalex.org/W2147810684","https://openalex.org/W2181161363","https://openalex.org/W2290515360","https://openalex.org/W2336127483","https://openalex.org/W2341711326","https://openalex.org/W2346704328","https://openalex.org/W2515900781","https://openalex.org/W2559769990","https://openalex.org/W2560848819","https://openalex.org/W2570527843","https://openalex.org/W2735827335","https://openalex.org/W2790027323","https://openalex.org/W2803404900","https://openalex.org/W3007559978","https://openalex.org/W4251433980"],"related_works":["https://openalex.org/W2905712023","https://openalex.org/W2803404900","https://openalex.org/W2790027323","https://openalex.org/W2331997928","https://openalex.org/W2047130177","https://openalex.org/W4295083464","https://openalex.org/W2528475754","https://openalex.org/W1915273926","https://openalex.org/W2807789068","https://openalex.org/W98730216"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Tralokinumab":[1],"is":[2],"a":[3,11,96,177],"monoclonal":[4],"antibody":[5,98],"(mAb)":[6],"that":[7,222],"neutralizes":[8],"interleukin":[9],"(IL)-13,":[10],"cytokine":[12],"involved":[13],"in":[14,71,78,202],"the":[15,28,219,228],"pathogenesis":[16],"of":[17,22,32,54,76,180,204],"asthma.":[18],"OBJECTIVE:":[19],"The":[20,51],"objectives":[21],"this":[23],"study":[24],"were":[25,60,69,107,140,195,209],"to":[26],"characterize":[27],"potential":[29],"immunogenic":[30],"properties":[31],"tralokinumab":[33,77,216,223],"and":[34,41,58,84,87,187,199,207],"report":[35],"data":[36],"for":[37,160,182,230],"anti-drug":[38],"antibodies":[39],"(ADAs)":[40],"hypersensitivity":[42,137,169,205,232],"reactions":[43],"from":[44],"two":[45,72],"phase":[46],"III":[47],"clinical":[48,74],"trials.":[49],"METHODS:":[50],"oligosaccharide":[52],"structure":[53],"tralokinumab,":[55],"Fab-arm":[56],"exchange,":[57],"ADAs":[59],"characterized":[61],"by":[62,162],"standard":[63],"techniques.":[64],"Hypersensitivity":[65],"adverse":[66],"events":[67,214],"(AEs)":[68],"evaluated":[70],"pivotal":[73],"trials":[75],"severe,":[79],"uncontrolled":[80],"asthma:":[81],"STRATOS":[82,110,128,143,152,185],"1":[83,186],"2":[85,112],"(NCT02161757":[86],"NCT02194699).":[88],"RESULTS:":[89],"mAb":[90],"(mavrilimumab).":[91],"However,":[92],"following":[93],"glutathione":[94],"reduction,":[95],"hybrid":[97],"with":[99,215],"monovalent":[100],"bioactivity":[101],"was":[102,191],"detected.":[103],"ADA":[104,189],"incidences":[105],"(titers)":[106],"as":[108,141],"follows:":[109,142],"1-every":[111],"weeks":[113,120],"(Q2":[114],"W)":[115,122],"0.8%":[116,126,134],"(26.0),":[117,124],"every":[118],"4":[119],"(Q4":[121],"0.5%":[123],"placebo":[125,133,150,156,200],"(52.0);":[127],"2-Q2":[129,153],"W":[130,145,148,154],"1.2%":[131],"(39.0),":[132],"(13.0).":[135],"Participant-reported":[136],"AE":[138],"rates":[139],"1-Q2":[144],"25.9%,":[146],"Q4":[147],"25.0%,":[149],"25.5%;":[151],"13.2%,":[155],"9.0%.":[157],"External":[158],"evaluation":[159],"anaphylaxis":[161,171,213],"Sampson":[163,211],"criteria":[164],"found":[165,196],"no":[166,193,210],"tralokinumab-related":[167],"severe":[168,231],"or":[170,233],"reactions.":[172,235],"CONCLUSION:":[173],"Preclinical":[174],"assessments":[175],"suggested":[176],"low":[178],"likelihood":[179],"immunogenicity":[181],"tralokinumab.":[183],"In":[184],"2,":[188],"incidence":[190],"low,":[192],"differences":[194],"between":[197],"tralokinumab-treated":[198],"groups":[201],"reporting":[203],"reactions,":[206],"there":[208],"criteria-evaluated":[212],"treatment.":[217],"Together,":[218],"results":[220],"suggest":[221],"treatment":[224],"would":[225],"not":[226],"increase":[227],"risk":[229],"anaphylactic":[234]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2909497384","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2019-01-25T00:00:00"}
